Greenwich LifeSciences

[Not Yet Scheduled]
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GLSI-100 to date over 4 clinical trials, treatment was well tolerated and no serious adverse events were observed related to the immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Ticker:
GLSI
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
GLSI-100 (GP2 + GM-CSF))
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1